OTTAWA, Aug. 15 /CNW/ - Liponex Inc. (TSX:LPX), a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called “good cholesterol,” announced today that Andrew Rae has resigned as a director of Liponex in order to concentrate on his responsibilities as President and CEO of iCo Therapeutics Inc. The Board of Directors would like to thank Mr. Rae for his many contributions as a director of the Company, including service on the Audit and Nomination and Corporate Governance committees.
